左心发育不良综合征综合管理策略:100例连续新生儿分析
本研究报道了单中心对100例连续左心发育不良综合征新生儿的综合管理策略及结局。按风险分层为3条路径:标准风险行Norwood一期手术(77例),高危非心脏因素行Hybrid一期(10例),高危心脏因素行Hybrid+心室辅助装置(VAD)或前列腺素桥接移植(13例)。总体1年死亡率为9%,Norwood术后手术死亡率为2.6%。
要点
- 标准风险患者行Norwood一期手术,手术死亡率为2.6%(2/77)。
- 高危非心脏因素患者行Hybrid一期手术,手术死亡率为10%(1/10)。
- 高危心脏因素患者中,Hybrid+VAD桥接移植者70%成功移植并存活。
核心结论
- 对左心发育不良综合征患者采用综合管理策略,Norwood术后手术死亡率为2.6%(2/77),总体1年死亡率为9%(9/100)。
- 10例患者(10%)通过Hybrid+VAD在等待移植期间稳定病情。
- VAD有助于在长时间等待期间维持生存。
研究设计与样本
- 单中心回顾性分析,纳入2015年1月1日至2023年9月1日连续100例左心发育不良综合征新生儿,按风险分层分为3条管理路径。
主要发现
- 路径1:77例(77%)标准风险患者行Norwood一期手术,手术死亡率为2.6%(2/77);75例存活者中72例行Glenn手术,2例行双心室修复,1例行心脏移植。
- 路径2:10例(10%)高危非心脏因素患者行Hybrid一期手术,手术死亡率为10%(1/10);9例存活者中4例行心脏移植,1例等待移植期间死亡,3例行综合二期手术(其中1例术后手术死亡),1例行双心室修复。
- 路径3:10例高危心脏因素患者行Hybrid+VAD,其中7例(70%)成功移植并存活,3例(30%)在VAD支持等待移植期间死亡;VAD支持中位时间为134天(范围56-226天)。
- 路径3中3例以前列腺素桥接移植的患者,2例成功移植,1例等待移植期间死亡。
临床怎么用
- 作者提出对左心发育不良综合征患者采用综合管理策略,按风险分层选择Norwood一期、Hybrid一期、Hybrid+VAD或前列腺素桥接移植。
- 作者认为VAD有助于在长时间等待移植期间维持生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report our comprehensive approach to the management of patients with hypoplastic left heart syndrome (HLHS) and describe our outcomes in 100 consecutive neonates. METHODS: We stratified 100 consecutive neonates (January 1, 2015 to September 1, 2023, inclusive) into 3 pathways. Pathway 1: 77 of 100 (77%) were standard risk and underwent an initial Norwood Stage 1. Pathway 2: 10 of 100 (10%) were high-risk with noncardiac risk factors and underwent an initial Hybrid Stage 1. Pathway 3: 13 of 100 (13%) were high-risk with cardiac risk factors: 10 underwent an initial Hybrid Stage 1 + Ventricular Assist Device insertion (HYBRID+VAD), and 3 were supported with prostaglandin as a planned bridge to primary cardiac transplantation. RESULTS: The overall 1-year mortality for the entire cohort of 100 patients was 9% (9 of 100). Pathway 1: Operative Mortality in Pathway 1 for the initial Norwood Stage 1 was 2.6% (2 of 77). Of the 75 survivors of Norwood Stage 1, 72 underwent successful Glenn, 2 underwent successful biventricular repair, and 1 underwent successful cardiac transplantation. Pathway 2: Operative Mortality in Pathway 2 for the initial Hybrid Stage 1 without VAD was 10% (1 of 10). Of 9 survivors of Hybrid Stage 1, 4 underwent successful cardiac transplantation, 1 died while awaiting cardiac transplantation, 3 underwent Comprehensive Stage 2 (with 1 Operative Mortality after Comprehensive Stage 2), and 1 underwent successful biventricular repair. Pathway 3: Of 10 patients supported with initial HYBRID+VAD in Pathway 3, 7 (70%) underwent successful cardiac transplantation and are alive today, and 3 (30%) died on VAD while awaiting transplantation. Median VAD support time was 134 days (range, 56-226 days). Of 3 patients who were bridged to transplant with prostaglandin, 2 underwent successful transplantation and 1 died while awaiting transplantation. CONCLUSIONS: A comprehensive approach to the management of patients with HLHS is associated with an Operative Mortality after Norwood of 2.6% (2 of 77) and an overall 1-year mortality of 9% (9 of 100). Ten patients (10%) were stabilized with HYBRID+VAD while awaiting transplantation. VAD facilitates survival on the waiting list during prolonged waiting times.
引用
- Bleiweis MS, Co-Vu J, Philip J, et al. Comprehensive Approach to the Management of Patients With Hypoplastic Left Heart Syndrome: Analysis of 100 Consecutive Neonates. Ann Thorac Surg. 2024. PMID: 38815850. doi:10.1016/j.athoracsur.2024.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。